**NIH funding opportunities** 

## Faculty of Medicine and Health Sciences: Research Development and Support 17 Aug 2016 (#27)

### [Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <u>www.grants.nih.gov</u>.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee <u>cdevries@sun.ac.za</u>) as soon as possible to inform of your intent to apply and then <u>confirm</u> at least 30 days before the submission date. The NIH grant is submitted institutionally. All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.

### Important notices

 New Policy Eliminates Most Appendix Material for NIH/AHRQ/NIOSH Applications Submitted for Due Dates On or After January 25, 2017 (NOT-OD-16-129)

### 1. Hypertension Outcomes for T4 REsearch within Lower Middle-Income Countries (Hy-TREC)

Letter of Intent due date: 30 days prior to the application due date Hyperlink: (<u>RFA-HL-17-014</u>) Type: U01 Application Due Date: November 8, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (to both Grants.gov and eRA Commons) on the application due date.

**Purpose**: The purpose of this FOA is to support research that identifies and studies regional- or national-level implementation strategies for evidence-based interventions for the prevention, treatment, and control of hypertension in adults in World Bank defined Lower-MICs. The FOA will support research that tests evidence-based implementation strategies that can accelerate regional and national scale-up of hypertension interventions and support high priority locally-driven late-stage (T4) implementation research.

**Budget**: NHLBI intends to fund up to 5 awards corresponding to a total of \$7,250,000, for fiscal years 2017 to 2021. Future year amounts will depend on annual appropriations. Application budgets may not exceed \$268,500 direct costs per fiscal year, but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

# 2. BRAIN Initiative: Development and Validation of Novel Tools to Analyze Cell-Specific and Circuit-Specific Processes in the Brain

Letter of Intent due date: October 2, 2016Hyperlink: (RFA-MH-17-220)Type: R01Application Due Date: November 2, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early<br/>to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.Applicants should be aware that on-time submission means that an application is submitted error free<br/>(to both Grants.gov and eRA<br/>Commons) on the application due date.

**Purpose**: The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

**Budget**: Issuing IC and partner components intend to commit an estimated total of \$5 million to fund 4-7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.



### 3. Secondary Analyses of Alcohol and Chronic Disease

Letter of Intent due date: N/A

### Hyperlink: (PA-16-395) Type (PA-16-394)

Type: R01 R03

**Application Due Date:** <u>Standard dates</u> & <u>Standard AIDS dates</u> Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. *Applicants should be aware that on-time submission means that an application is submitted error free* (to both Grants.gov and eRA Commons) on the application due date.

**Purpose**: This Funding Opportunity Announcement (FOA) encourages applications that propose to conduct secondary analyses of alcohol as it relates to chronic disease etiology and epidemiology. The goal of this program is to facilitate innovative yet cost-effective research utilizing previously collected data.

**Budget**: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. R01=Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project may not exceed 5 years. R03 = Application budgets are limited to \$50,000 in direct costs per year. The total project may not exceed 2 years.

4. Engineering Next-Generation Human Nervous System Microphysiological Systems		
Letter of Intent due date: N/A	Hyperlink: <u>(PAR-16-397)</u>	Type: R21
	<u>(PAR-16-398)</u>	R01

**Application Due Date:** <u>Standard dates</u> & <u>Standard AIDS dates</u> Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. *Applicants should be aware that on-time submission means that an application is submitted error free* (to both Grants.gov and eRA Commons) on the application due date.

**Purpose**: This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) with improved fidelity to complex human brain, spinal, peripheral nervous system and/or sensory end organ circuit physiology in vivo, which will ultimately facilitate analysis of higher order functional deficits relevant to complex nervous system disorders.

**Budget**: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. R21 = The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01 = Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: comprehensive list of extramural grant and cooperative agreement activity codes

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, smallcontained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

#### Glossary of selected acronyms:

FOA Funding Opportunity Announcement

- PA Program Announcements (click on "PA" to search for further funding opportunities)
- **<u>RFA</u>** Request for Applications (click on "RFA" to search for further funding opportunities)

Complete Glossary and acronym list of NIH Terms

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University 5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: Dr Christa Coetsee • Tel: 9838 • Email: <u>cdevries@sun.ac.za</u>